Switzerland/ La Jolla CA, 11 December
2013 – BioWa, Inc. and Lonza today announced that they have entered into
a licensing agreement with MedImmune, the global biologics research and
development arm of AstraZeneca.
MedImmune has licensed the companies’ POTELLIGENT® CHOK1SV Cell Line Technology
for use in multiple proprietary antibodies in its pipeline.
CHOK1SV is a host cell line for manufacturing recombinant antibodies that
combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology
with the advantages of Lonza’s industry leading GS Gene Expression System™. The GS System™ includes Lonza’s pre-eminent
host cell line, CHOK1SV. POTELLIGENT® Technology
is designed to improve the potency and efficacy of therapeutic
antibodies by enhancing antibody-dependent cellular
cytotoxicity (ADCC), one of the major mechanisms of
MedImmune entered into a previous licensing
agreement with BioWa in 2007 for POTELLIGENT® Technology. Today’s agreement incorporates Lonza’s
technology to the existing POTELLIGENT® Technology.
are very pleased to extend our
relationship with MedImmune, a global biologics company who has recognized the
core value of POTELLIGENT® Technology for the development of antibody-dependent
cellular cytotoxicity enhanced antibodies,” said Yasunori Yamaguchi Ph.D., President and
CEO of BioWa.
CHOK1SV Cell Line retains the features of a high-producing cell line (robust,
high-yielding, scalable), with the advantage of a proven bioprocess platform
for the CHOK1SV Cell Line. Antibodies produced by this cell line exhibit
enhanced ADCC and can exert potent cytotoxic effects even when their target
antigen is low. In addition, they work in whole blood and retain all other
desirable features of common antibodies.
“It is a pleasure
for us to enter to this agreement with MedImmune and BioWa,” said Karen Fallen,
VP Head of Licensing, Lonza Custom Development Services. The combination of Lonza’s well-known GS System™
coupled with POTELLIGENT® CHOK1SV Cell Line provides our customers with a significant
advantage in expression technology.”
of the technologies from BioWa and Lonza will help enhance our ability to
produce high quantity potent antibodies for preclinical and clinical
development programs, which is a key driver in making better medicines to treat
patients,” said Herren Wu, Vice President, Research & Development, Global
Head of Antibody Discovery and Protein Engineering, MedImmune.
CHOK1SV Cell Line is available under a license agreement with Lonza and BioWa. For
more information on accessing the POTELLIGENT® CHOK1SV Technology, please